Response to H pylori eradication treatment in patients with platelets less then 30 × 109/L
| Patient no. . | Age in y, sex . | Duration, mo . | H pylori infection . | Platelets, × 109/L . | Follow-up, mo. . | Present condition . | |
|---|---|---|---|---|---|---|---|
| Before . | After (at 6 mo) . | ||||||
| 1 | 69, M | 7 | Yes | 29 | 190* | 46 | CR |
| 10 | 77, F | 21 | Yes | 27 | 172* | 79 | CR† |
| 50 | 37, M | 14 | Yes | 27 | 246* | 31 | CR |
| 7 | 60, M | 15 | Yes | 25 | 176* | 80 | CR |
| 49 | 37, M | 18 | Yes | 25 | 99* | 32 | PR |
| 54 | 52, F | 7 | Yes | 20 | 235* | 26 | CR |
| 55 | 77, F | 21 | Yes | 18 | 187* | 26 | CR |
| 12 | 89, M | 13 | Yes | 15 | 35 | 34 | NR‡ |
| 44 | 85, F | 9 | Yes | 12 | 195* | 23 | Died in CR |
| 41 | 78, M | 7 | Yes | 10 | 20 | 44 | NR-P |
| 46 | 18, F | 9 | Yes | 9 | 22 | 41 | NR-P |
| 47 | 47, M | 186 | Yes | 6 | 173* | 39 | CR |
| 53 | 26, F | 7 | Yes | 2 | 485* | 28 | CR |
| 59 | 34, M | 7 | Yes | 1 | 12 | 18 | NR-P |
| 65 | 36, F | 8 | No | 25 | 100 | 32 | P-stable |
| 71 | 91, F | 9 | No | 25 | 90 | 27 | P-stable |
| 73 | 47, M | 7 | No | 25 | 90 | 19 | P-stable |
| 66 | 26, M | 7 | No | 24 | 115 | 31 | P |
| 68 | 85, F | 8 | No | 20 | 80 | 29 | Dead |
| 61 | 68, M | 9 | No | 15 | 95 | 39 | P |
| 72 | 24, M | 8 | No | 12 | 85 | 25 | P-stable |
| 62 | 81, F | 12 | No | 5 | 248 | 34 | Stable |
| 25 | 64, M | 31 | No | 2 | 120 | 81 | Stable |
| 60 | 57, M | 7 | No | 1 | 113 | 41 | P |
| Patient no. . | Age in y, sex . | Duration, mo . | H pylori infection . | Platelets, × 109/L . | Follow-up, mo. . | Present condition . | |
|---|---|---|---|---|---|---|---|
| Before . | After (at 6 mo) . | ||||||
| 1 | 69, M | 7 | Yes | 29 | 190* | 46 | CR |
| 10 | 77, F | 21 | Yes | 27 | 172* | 79 | CR† |
| 50 | 37, M | 14 | Yes | 27 | 246* | 31 | CR |
| 7 | 60, M | 15 | Yes | 25 | 176* | 80 | CR |
| 49 | 37, M | 18 | Yes | 25 | 99* | 32 | PR |
| 54 | 52, F | 7 | Yes | 20 | 235* | 26 | CR |
| 55 | 77, F | 21 | Yes | 18 | 187* | 26 | CR |
| 12 | 89, M | 13 | Yes | 15 | 35 | 34 | NR‡ |
| 44 | 85, F | 9 | Yes | 12 | 195* | 23 | Died in CR |
| 41 | 78, M | 7 | Yes | 10 | 20 | 44 | NR-P |
| 46 | 18, F | 9 | Yes | 9 | 22 | 41 | NR-P |
| 47 | 47, M | 186 | Yes | 6 | 173* | 39 | CR |
| 53 | 26, F | 7 | Yes | 2 | 485* | 28 | CR |
| 59 | 34, M | 7 | Yes | 1 | 12 | 18 | NR-P |
| 65 | 36, F | 8 | No | 25 | 100 | 32 | P-stable |
| 71 | 91, F | 9 | No | 25 | 90 | 27 | P-stable |
| 73 | 47, M | 7 | No | 25 | 90 | 19 | P-stable |
| 66 | 26, M | 7 | No | 24 | 115 | 31 | P |
| 68 | 85, F | 8 | No | 20 | 80 | 29 | Dead |
| 61 | 68, M | 9 | No | 15 | 95 | 39 | P |
| 72 | 24, M | 8 | No | 12 | 85 | 25 | P-stable |
| 62 | 81, F | 12 | No | 5 | 248 | 34 | Stable |
| 25 | 64, M | 31 | No | 2 | 120 | 81 | Stable |
| 60 | 57, M | 7 | No | 1 | 113 | 41 | P |
Data represent patients with ITP with platelet counts less than 30 × 109/L. Disease duration data from Table 2. For uninfected patients, platelet values are before and after immunosuppressive therapy.
P indicates intermittent prednisone.
Eradication-responsive patients.
Relapse 7 months after eradication.
Lost follow-up.